Takeda to build manufacturing plant in Germany for €100M: 4 key notes

Japan's Takeda Pharmaceutical is investing more than €100 million in a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

Here's what you need to know.

1. Dengue is "the fastest spreading mosquito-borne viral disease," according to the World Health Organization. It has caused an estimated 390 million infections and 20,000 deaths on a yearly basis.

2. Global Manufacturing & Supply Officer at Takeda Thomas Wozniewski, MD, said the plant will serve millions of people.

3. Initial construction activity is underway with the plant expected to begin production in 2019.

4. Takeda is running a clinical trial for its Tetravalent Immunization against Dengue Efficacy Study. It's enrolling 20,000 healthy children into a Phase 3 double-blind, randomized, placebo-controlled trial.

The study is evaluating the efficacy of the vaccine against dengue fever.

President of Takeda Vaccines Rajeev Venkayya, MD, said the vaccine is "another strong indication of Takeda's long term commitment to vaccines."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 


Patient Safety Tools & Resources Database

Featured Webinars

Featured Whitepapers

Featured Podcast